Other
Aphthous Ulcer
14
Pipeline Programs↗
5
Active Trials↗
5
Companies Involved↗
Aphthous Ulcer is an emerging landscape with 14 programs across 5 companies. The most active players are Bristol-Myers Squibb, Kenvue Brands, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 6 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Analysis
Trial Status
12
clinical trials
Completed5 · 42%
Unknown status2 · 17%
Not yet recruiting2 · 17%
Recruiting2 · 17%
Active, not recruiting1 · 8%
Clinical Trials
Trial Activity
12 trials
Oxygenated Gel Therapy in the Management of Oral Aphthous Ulcers
Recruiting·—·Phase 2/3·NCT06910579·30 enrolled
Efficacy of Thyme Honey in The Management of Oral Aphthous Ulcers
Not yet recruiting·—·N/A·NCT06421038·20 enrolled
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000790·164 enrolled
Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration
Completed·—·Phase 3·NCT00857688·100 enrolled
Clinical Evaluation of Topical Coenzyme Q10 in Management of Oral Aphthous Ulcer
Unknown status·—·N/A·NCT03213769·52 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)